Related Experiment Video
Updated: Jun 8, 2025
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
Engineering and targeting potential of CAR NK cells in colorectal cancer
Muhammad Babar Khawar1,2,3, Ali Afzal1,4, Shuangshuang Dong1,5
1Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu 225009, China.
Abstract:
Colorectal cancer (CRC), a major global health concern, necessitates innovative treatments. Chimeric antigen receptor (CAR) T cells have shown promises, yet they grapple with challenges. The spotlight pivots to the rising heroes: CAR natural killer (NK) cells, offering advantages such as higher safety profiles, cost-effectiveness, and efficacy against solid tumors. Nevertheless, the specific mechanisms underlying CAR NK cell trafficking and their interplay within the complex tumor microenvironment require further in-depth exploration. Herein, we provide insights into the design and engineering of CAR NK cells, antigen targets in CRC, and success in overcoming resistance mechanisms with an emphasis on the potential for clinical trials.
Insights
Chimeric antigen receptor (CAR) natural killer (NK) cells show promise for treating colorectal cancer (CRC). Further research is needed to understand CAR NK cell trafficking and tumor microenvironment interactions for clinical applications.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- Colorectal cancer (CRC) is a significant global health challenge requiring novel therapeutic strategies.
- Chimeric antigen receptor (CAR) T cells offer potential but face limitations.
- CAR natural killer (NK) cells are emerging as a promising alternative with improved safety, cost-effectiveness, and efficacy in solid tumors.
Purpose of the Study:
- To explore the potential of CAR NK cells in treating colorectal cancer.
- To investigate the mechanisms of CAR NK cell trafficking and tumor microenvironment interactions.
- To provide insights into CAR NK cell design, engineering, and antigen targeting for CRC.
Main Methods:
- Review of current research on CAR NK cell technology.
- Analysis of potential antigen targets for CAR NK cell therapy in CRC.
- Discussion of strategies to overcome tumor resistance mechanisms.
Main Results:
- CAR NK cells present advantages over CAR T cells, including enhanced safety and broader applicability to solid tumors.
- Understanding CAR NK cell trafficking and tumor microenvironment interplay is crucial for optimizing efficacy.
- Engineering CAR NK cells with specific antigen targets can overcome CRC resistance.
Conclusions:
- CAR NK cells represent a promising and potentially safer immunotherapy for colorectal cancer.
- Further investigation into CAR NK cell mechanisms and clinical trial design is warranted.
- CAR NK cell therapy holds significant potential for advancing CRC treatment paradigms.
More Related Videos
08:29Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System
Published on: October 4, 2024
11:02Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
Published on: February 8, 2022
